Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Apremilast in Moderate to Severe Genital Psoriasis
2018-002608-15Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Apremilast arm with Placebo arm (2 arms). Primary endpoint: Static Physician Global Assessment of Genitalia (sPGA-G) 0/1 (modified). Started Dec 2018; status: completed.
02
Drugs
apremilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2018-002608-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002608-15.